Heart failure (HF) burden in people with type 2 diabetes (T2D)

HF is a frequent condition occurring in patients with diabetes (DM) (1,2). Diabetic men and women display a 6 to 8-fold increase in the prevalence of HF, with the highest number of cases observed in the latter group (3). Among patients with HF, 15-26% has DM, a condition which amplifies morbidity and mortality (4-6). The recent ATLAS study showed that the proportion of DM patients with HF may reach 20% (7). HF patients with concomitant DM have a further increase in morbidity and mortality due to coexistence of several mechanisms including disturbed neurohormonal axis as well as structural and functional abnormalities occurring in the diabetic myocardium (8).

About one fifth of patients with chronic HF has DM, and such prevalence reaches 40% for patients with worsening HF (5). T2D individuals are at increased risk for both HF with preserved (HFPEF) and reduced (HFREF) ejection fraction (9). Notably, prospective analyses have shown that poor glycemic control—as indicated by HbA1c levels—may be associated with an increased risk of HF, this issue remains poorly understood and further evidence is required to show unequivocal benefits of this approach. In the attempt to explore the effects of new anti-hyperglycemic therapies, randomized trials have shown that some glucose-lowering drugs—thought not affecting cardiovascular (CV) death or ischemic complications—might significantly increase the risk of HF-hospitalizations in DM patients. Specifically, the use of dipeptidyl-peptidase-4 (DDP-4) inhibitors (DDP-4i) has recently raised a major safety concern owing to an increase of HF hospitalizations in SAVOR-TIMI 53 trial. In contrast with these findings, the more recent TECOS study as well as new TECOS sub-analyses presented at the last ESC Congress—have yielded to the conclusion that the DPP-4i sitagliptin is not associated with any sort of HF risk. Therefore, increased risk of HF hospitalizations does not seem to be a class effect of DPP-4i. The present article critically discusses available evidence concerning DPP-4i and risk of HF in patients with type 2 diabetes (T2D). The use of DPP-4i in combination therapy is also discussed, in light of the recent EMPA-REG trial.

Keywords: Type 2 diabetes (T2D); DDP-4 inhibitors; heart failure (HF); cardiovascular disease (CVD); clinical trials; safety
Does glycemic control reduce the risk of HF in diabetic patients?

Several studies have shown that poor glycemic control, as indicated by glycated haemoglobin (HbA\textsubscript{1c}) levels, is associated with an increased risk of HF. The UKPDS study which included patients with newly diagnosed DM, showed a significant association between long-term glycemic control and HF risk. In this study, the adjusted rate of HF was reduced to 2.3 events/100 person-years in those with HbA\textsubscript{1c} levels <6%, from 11.9 in those whose HbA\textsubscript{1c} levels were >10%, with a near linear relationship between lowering of HbA\textsubscript{1c} and risk of HF (12). Unfortunately, these data could not be confirmed by the recent randomized controlled trials ACCORD, ADVANCE and VADT which tested the effects of intensive glycemic control on micro and macrovascular outcomes (13). In these studies, the achievement of target HbA\textsubscript{1c} values (<7%) was not associated with a reduction of HF-related hospitalizations. In line with such disappointing results, a recent meta-analysis including 7 randomized controlled trials with a total of 37,229 patients showed that the risk of HF-related events did not differ significantly between intensive glycemic control and standard treatment (OR 1.20, 95% CI 0.96-1.48), tough effect estimate was highly heterogeneous (14). Indeed, among the 4 trials that had a high rate of thiazolidinediones use (i.e., PROactive, ACCORD, VADT, and RECORD), the risk of HF was elevated in individuals randomized to intensive blood glucose control. On the other hand, among the remaining 3 trials (i.e., UKPDS, ADVANCE, and VACSDM), the risk ratio was close to null with a wide CI, highlighting the limitedness of the available data (risk ratio, 0.96; 95% CI: 0.81-1.13) (14).

It is therefore difficult to conclude that hyperglycemia may not be relevant in HF patients and further studies are needed to clarify this important issue. In contrast with this meta-analysis, an earlier cohort study including 25,958 men and 22,900 women with T2D demonstrated that each 1% increase in HbA\textsubscript{1c} was associated with an 8% increased risk of HF (95% CI: 5-12%) (15). In this study, an HbA\textsubscript{1c} ≥10, relative to HbA\textsubscript{1c} <10 was associated with 1.56-fold (95% CI: 1.26-1.93) greater risk of HF. Similarly, in the Reykjavik Study, a linear and independent relationship between increasing fasting plasma glucose and the development of HF was observed (16). More recently, in a clinical trial cohort of 531,546 subjects at high CV risk followed-up for a mean of 2.4 years, Held et al. showed that dysglycemia was an independent predictor of hospitalization for HF regardless of DM status (17). Collectively, these data suggest that (I) glycemic burden may be important for HF occurrence and hospitalization; and (II) choice of glucose lowering drugs may affect HF risk in DM patients.

The recent case of DPP-4 inhibitors

Available anti-diabetic drugs are effective for the management of hyperglycemia, however many DM patients have cardiovascular (CV) problems and attention should be paid to the risk/benefit ratio of the different formulations (18). Thiazolidinediones, namely rosiglitazone, are associated with a number of complications including bladder cancer, bone fractures, fluid retention with increased body weight, and last but not least, risk of HF (13). Moreover, insulin may induce fluid retention although it did not affect the risk of HF in the ORIGIN trial (19).

In the attempt to explore the effects of new anti-hyperglycemic therapies, recent randomized trials unveiled an increase in the risk of HF-hospitalizations in DM patients treated with the dipeptidyl-peptidase-4 (DDP-4) inhibitors (DPP4i) as compared to placebo (20). Before moving into the interpretation of clinical findings it is appropriate to mention how DPP-4i work and what is the experimental background supporting putative CV benefits of this class of drugs.

DPP-4i block the degradation of glucagon like peptide-1 (GLP-1), gastric inhibitory peptide (GIP) and a variety of other peptides including brain natriuretic peptide. Therefore, these drugs raise GLP-1/gastric inhibitory polypeptide levels resulting in enhancement of inotropenic effects of glucose (21). Experimental evidence supports the notion that DPP-4 are important drivers of myocardial damage (22). Indeed, mice with genetic deletion of DDP-4 display longer survival rates following myocardial infarction (MI) (23,24). This observation was explained by increased cardiac expression of phosphorylated AKT (pAKT), pGSK3beta, and atrial natriuretic peptide (ANP) in Dpp4\textsuperscript{−/−} hearts. Interestingly, treatment with the DPP-4i sitagliptin was able to recapitulate these molecular changes
thereby protecting against myocardial ischemic damage (23).

Accordingly, sitagliptin treatment in patients with or without T2D was associated with a significant recovery of the ischemic myocardium, as assessed by dobutamine stress echocardiography (25). Taken together, these data suggest that DDP-4 inhibition may represent an attractive mechanism-based approach fostering cardioprotective pathways in the failing and ischemic myocardium (21).

### Lessons from SAVOR-TIMI 53 and EXAMINE trials

Current evidence suggests that such experimental findings are somehow “lost in translation”. Indeed, recent clinical trials which were launched to test CV effects of DPP-4i not only failed to show any DDP4-related CV benefit, but were even associated with an increase in HF hospitalizations (20).

In the SAVOR-TIMI 53 trial, 16,492 T2D patients who had a history of, or were at risk for, CV events, were randomized to receive saxagliptin or placebo and followed for a median of 2.1 years (Table 1) (26). A primary endpoint event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, HR, 1.00; 95% CI: 0.89-1.12; P=0.99 for superiority; P<0.001 for noninferiority). The major

| Table 1 | Main clinical features and outcomes of SAVOR TIMI 53, EXAMINE and TECOS trials |
|---------|-----------------------------------|-----------------------------------|
|         | SAVOR-TIMI 53 (26)               | EXAMINE (27)                       | TECOS (28)                       |
| Number of patients | 16,492               | 5,380               | 14,671               |
| Population | T2D patients with CVD or high CV risk | T2D with an acute MI or UA requiring hospitalization within the previous 15-90 days | T2D patients with CVD or high CV risk |
| Intervention | Saxagliptin vs. placebo | Alogliptin vs. placebo | Sitagliptin vs. placebo |
| Mean age (years) | 65               | 61               | 65               |
| Diabetes duration (years) | 10               | 7               | 11.6               |
| Established CVD (%) | 78               | 100               | 74               |
| Mean HbA1c (%) | 8±1.4             | 8±1.1             | 7.2±0.5             |
| BMI (Kg/m²) | 31               | 28.7             | 30.2               |
| Prior HF | 12.8             | 28               | 18               |
| Median follow-up (years) | 2.1             | 1.8             | 3.0               |
| Hypoglycemia |                           |                    |                   |
| Intervention | 15.3             | 6.7             | 2.0               |
| Placebo | 13.4             | 6.5             | 1.7               |
| Definition of primary outcome | CV death, non-fatal MI, non-fatal ischemic stroke | CV death, non-fatal MI, non-fatal stroke | CV death, non-fatal MI, non-fatal stroke, or UA hospitalization |
| HR for primary outcome | 1.00 (0.89-1.12) | 0.96 (≤1.16) | 0.98 (0.89-1.08) |
| Definition of secondary outcome | CV death, MI, stroke, hospitalization for UA, HF, or coronary revascularization due to UA within 24 hours after hospital admission | Primary outcome + urgent revascularization | CV death, nonfatal MI, or nonfatal stroke |
| HR for secondary outcome | 1.02 (0.94-1.11) | 0.95 (≤1.14) | 0.99 (0.89-1.10) |
| Hospitalization for HF | 1.27 (1.07-1.51) | 1.19 (0.89-1.59) | 1.00 (0.84-1.20) |
| CV mortality | 1.22 (1.01-1.46) | 0.85 (0.66-1.10) | 1.03 (0.89-1.19) |
| All-cause mortality | 1.11 (0.96-1.27) | 0.88 (0.71-1.09) | 1.01 (0.90-1.14) |

T2D, type 2 diabetes; CVD, cardiovascular disease; BMI, body mass index; HF, heart failure; HR, hazard ratio; UA, unstable angina; MI, myocardial infarction.
secondary end point of a composite of CV death, MI, stroke, hospitalization for unstable angina (UA), coronary revascularization, or HF occurred in 1,059 patients in the saxagliptin group and in 1,034 patients in the placebo group (12.8% and 12.4%, respectively, HR, 1.02; 95% CI: 0.94-1.11; P=0.66). Unexpectedly, more patients in the saxagliptin group than in the placebo group were hospitalized for HF (3.5% vs. 2.8%; HR, 1.27; 95% CI: 1.07-1.51; P=0.007) (26). Corresponding rates at 12 months were 1.9% vs. 1.3% (HR, 1.46; 95% CI: 1.15-1.88; P=0.002), with no significant difference thereafter (time-varying interaction, P=0.017). However, these findings were not paralleled by a concomitant increase in HF-related deaths in patients taking saxagliptin (44 and 40 cases in saxagliptin and placebo, respectively) (26). Subjects at greatest risk of HF hospitalization had previous HF, an estimated glomerular filtration rate ≤60 mL/min, or elevated baseline levels of N-terminal pro B-type natriuretic peptide. There was no evidence of heterogeneity between N-terminal pro B-type natriuretic peptide and saxagliptin (P for interaction =0.46), although the absolute risk excess for HF with saxagliptin was greatest in the top pro-BNP quartile (HR, 1.31; 95% CI: 1.04-1.66; P=0.02), whereas the lowest quartile was not associated with any treatment difference (0.6% and 0.6%, HR, 0.84; 95% CI: 0.46-1.52; P=0.56) (29). Another concern was represented by differences in glycemic status between groups. Although designed as a glycemic equipoise study, fasting plasma glucose as well as HbA1c significantly differed among patients allocated to saxagliptin and placebo. In line with this data, a larger number of minor (P=0.002) and major (P=0.047) hypoglycemic episodes were recorded in the saxagliptin arm (Table 1).

In the EXAMINE trial, 5,380 patients with T2D and acute coronary syndrome in the preceding 90 days, were randomized to treatment with the DPP-4i alogliptin or placebo (27). This double-blind, non-inferiority trial showed no differences in primary and secondary CV endpoints between alogliptin and placebo after a mean follow up of 4 years. In contrast with SAVOR-TIMI 53, this study did not show outcome differences as far as HF is concerned. There was a 7% non-significant increase in the alogliptin arm (3.1% vs. placebo group (2.9%). However, post-hoc analyses revealed that the rate of HF was increased in patients taking DPP-4i who had signs of HF (HR, 1.76; 95% CI: 1.07-2.90) (13,30). As observed in SAVOR-TIMI 53, data from EXAMINE confirmed that the risk of hospital admission for HF was highest among patients with BNP concentrations in the top quartile at baseline (30).

The lack of statistical significance for HF hospitalization in EXAMINE is likely driven by a much smaller sample size as compared to SAVOR trial (5,380 vs. 16,492 patients) (31). Hence, the study might not be powered enough as far as secondary endpoint is concerned. Along this line, a recent meta-analysis including SAVOR and EXAMINE trials has confirmed a 25% increase of HF hospitalizations related to DPP-4i (32). On the whole, these data may suggest that the increased risk of HF hospitalization with DPP-4i is likely to be a concrete and previously unrecognized side effect. A putative mechanisms which may contribute to explain the increased risk of HF hospitalizations with DPP-4i is the alteration of several neurohormonal axes, namely substance P (SP) and neuropeptide Y (NP-Y) (28). A recent study conducted in patients with the metabolic syndrome, showed that during placebo and low-dose ACE inhibition (5 mg enalapril), sitagliptin lowered blood pressure (33). However, this trend was reversed in those patients taking ACE inhibitors at higher doses. These findings led the authors to postulate that in patients taking a combination of sitagliptin and high-dose ACE inhibition, high levels of SP may foster sympathetic tone activation, thereby attenuating blood pressure reduction (33). Indeed, SP and NP-Y are detrimental bioproducts of DPP-4 inhibition which may trigger sympathetic activity and, hence, HF worsening in T2D patients. Against this, the analysis of SAVOR-TIMI 53 trial showed that the risk of HF hospitalization was higher among T2D patients who were not on ACE inhibitors (HR, 1.42; 95% CI: 1.09-1.88) as compared to those who were taking this class of drugs (HR, 1.18; 95% CI: 0.94-1.48) (20). Longer duration and prospective studies are needed to prove these novel findings and effects.

**All eyes on safety: the TECOS trial**

Based on these safety concerns, international regulatory agencies have required that DPP-4i—as well as other new glucose lowering drugs—not only show glucose-lowering ability but also are not associated with clinically meaningful increases in rates of major adverse CV events. In this regard, the main concern is whether HF worsening is a class effect of all DPP-4i or is rather linked to specific molecules within this family. The answer to this important question came from the recent TECOS trial which was launched to assess non inferiority as well as long-term CV safety of adding sitagliptin to usual care, as compared with usual care alone, in 14,671 patients with T2D and established CVD (Table 1) (34). During a median follow-up
of 3.0 years, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%) and 851 patients in the placebo group (11.6%). Sitagliptin was non-inferior to placebo for the primary composite CV outcome (HR, 0.98; 95% CI: 0.88-1.09; P<0.001). In this trial, the intention to treat (ITT) analysis showed similar outcome rates as far as HF hospitalization is concerned (HR, 1.00; 95% CI: 0.83-1.20; P=0.98). In contrast with SAVOR and EXAMINE, TECOS analysis of HF-related outcomes and CV death was performed according to FDA safety standards within the ITT population. Again, this did not show any additional risk for diabetic patients receiving sitagliptin (HR, 1.02; 95% CI: 0.90-1.15; P=0.74). Moreover, the rate of all-cause mortality was comparable in the two arms. Of note, sitagliptin was not associated with a significant risk of hypoglycemia (HR, 1.12; 95% CI: 0.89-1.40) (34). The notion that sitagliptin does not adversely impact on HF hospitalizations was further strengthened by a very recent sub-analysis of TECOS, presented in London at the last Congress of the European Society of Cardiology (ESC). The initial TECOS findings, presented earlier this year at the American Diabetes Association, were adjusted to control for baseline HF. According to a press release from the ESC, new data from TECOS show unadjusted and adjusted analyses (also pre-specified) with identical results (HR, 1.00; 95% CI: 0.84-1.20; and HR, 1.02; 95% CI: 0.83-1.26) (35). The stability of these findings was confirmed across a very extensive set of complementary/sensitivity analyses—all yielding to the conclusion of no signal of any sort of HF risk with sitagliptin.

The implications of such analysis will be very important for endocrinologists, but also for cardiologists who see many patients with T2D and coronary heart disease treated with sitagliptin. Therefore, patients with T2D and CVD can safely take the anti-hyperglycemic drug sitagliptin without an increased risk of CV complications—even if they have a history of HF. These encouraging data strongly suggest that increased HF risk is not a class effect of DPP-4i. This postulate is strengthen by the results of observational studies showing a neutral effect or even a benefit of DPP-4i on HF-related outcomes (36,37). Nonetheless, further evidence is needed to draw solid conclusions on the safety of saxagliptin and alogliptin in people with T2D and CVD.

Open issues

An important clinical question to answer is how DPP-4i perform when compared with other glucose-lowering agents as far as HF-related risk is concerned. A very recent retrospective study including 127,555 unmatched T2D patients extracted from a population of 18 million individuals reported data on patients who initiated treatment with DPP-4i, thiazolidinediones, or sulphonylureas alone or in combination with metformin (38). During an average 2.6-year follow-up, after adjusting for measured confounders, the use of DPP-4i was associated with a reduced risk of HF hospitalizations as compared with sulphonylureas (HR, 0.78; 95% CI: 0.62-0.97; P=0.026). Interestingly enough, DPP-4i remained associated with a lower risk of HF hospitalization even after propensity matching (HR, 0.70; 95% CI: 0.52-0.94; P=0.018). The 28-30% lower risk of HF hospitalization detected with DPP-4i may thus derive from a beneficial protective effect of DPP-4i or from a detrimental effect of sulphonylureas on HF. Indeed, sulphonylureas have been associated with an increased risk of HF as compared with metformin (39). On the whole, these results do not presume to demonstrate unequivocal benefits of DPP-4i vs. sulphonylureas, they rather provide a wide and insightful snapshot on how different anti-diabetic drugs may affect HF risk in a population-based registry. Undoubtedly, further research is warranted to further appraise the individual effect of different glucose-lowering drugs on HF-related outcomes.

Another aspect deserving attention relates to the identification of T2D patients who should receive therapy with DPP-4i in clinical practice. This is of particular importance in light of the very recent EMPA-REG trial, showing that an inhibitor of sodium-glucose cotransporter 2 (SGLT2) yielded to a 14% reduction of the primary end point of death from CV causes, non-fatal MI and non-fatal stroke (HR, 0.86; 95% CI: 0.74-0.99), a 38% reduction of CV mortality (HR, 0.62; 95% CI: 0.49-0.77) as well as a 35% reduction in HF hospitalizations (HR, 0.65; 95% CI: 0.50-0.85) in T2D patients with established CVD (40). For the first time, a DM trial clearly demonstrated that a glucose-lowering agent, namely the SGLT2 inhibitor empagliflozin, may profoundly affect the natural history of CV complications in patients with T2D. SGLT2 inhibitors reduce plasma glucose concentration by inhibiting renal glucose reabsorption and producing glucosuria (41). Given as either monotherapy or as an add-on therapy, these drugs are reported to reduce HbA1c levels in T2D patients, including those with stage 2 or 3a chronic kidney disease. However, T2D is a complex disorder involving multiple metabolic defects and its management often requires the use of combination therapies eventually yielding to an
additive reduction in HbA$_1c$ levels (42). Over the last few years, several randomized trials have investigated whether the combination of DPP-4i and SGLT2 inhibitors would provide additional benefit as far as glycemic control is concerned. The rationale of using such combination is based on the notion that SGLT2-induced glycosuria causes a compensatory increase of endogenous glucagone levels which offsets their glucose-lowering effect by approximately 50%. On the other hand, DPP4i have the ability to suppress glucagone secretion thereby blunting endogenous production of the hormone. However, such synergic effects have been only partially demonstrated in T2D patients receiving a combination therapy with DPP-4i and SGLT2 inhibitors (43). In the recent study by Rosenstock et al. 534 poorly controlled, metformin-treated T2D patients were randomized to receive dapagliflozin alone, saxagliptin alone, or a combination of saxagliptin plus dapagliflozin over a period of 24 weeks (44). Saxagliptin and dapagliflozin lowered HbA$_1c$ levels by 0.88% and 1.2%, respectively, whereas their combination yielded to a 1.47% reduction, which is significantly lower than expected from this approach (43). Consistently, another recent study showed that reductions in HbA$_1c$ with the combination emagliflozin/linagliptin were superior to those with emagliflozin or linagliptin alone as add-on to metformin, even though the differences were not striking (45). Taken together, these findings suggest that, even if well tolerated, the overall additional benefit from the combination DPP-4i/SGLT2 is rather small and may raise concerns on the cost-effectiveness of such an approach. In other words, it is important to understand whether anti-hyperglycemic therapy with DPP-4i can be safely implemented in T2D patients taking empagliflozin. This concern particularly applies to those patients with HF or at high risk of developing this complication overtime.

Acknowledgements

None.

Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.

References
